Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA's Media Frenzy

This article was originally published in RPM Report

Executive Summary

The Food & Drug Administration is trying to reverse its negative image tide by adopting a more proactive relationship with the news media. Over one five-week period alone, FDA held almost a dozen media teleconference calls on drug- or biologic-related issues. The extra attention is either good or bad news for manufacturers, depending on the subject of the media briefing.

You may also be interested in...



Avandia and the Commercial Impact of FDA's Credibility Gap

GlaxoSmithKline's diabetes drug Avandia survived a perilous FDA advisory committee review. The real question is whether the industry can survive the damage to FDA's credibility.

FDA on Spin Cycle

An FDA advisory committee call for immediate action on attention deficit/hyperactivity disorder drug safety leaves the agency scrambling to defend itself.

FDA "Lock-Ups" Aimed At Cutting Down Surprises

FDA plans to "lock up" reporters before major drug safety announcements in order to brief them more thoroughly and give them access to agency experts. FDA is working on a policy paper related to its external relations efforts.

Topics

Related Companies

UsernamePublicRestriction

Register

PS080103

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel